<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334671</url>
  </required_header>
  <id_info>
    <org_study_id>W2-2009041</org_study_id>
    <nct_id>NCT01334671</nct_id>
  </id_info>
  <brief_title>The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCI</brief_title>
  <official_title>The Clinical Effect of Intensive Statin Therapy in STEMI(ST-elevated Myocardial Infarction) Patients Before Emergency PCI(Percutaneous Coronary Intervention)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Chinese Armed Police Forces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical effect of intensive statin therapy
      before emergency PCI in patients with STEMI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 STEMI patients planned for emergency PCI were randomized to three groups, Group
      1:received atorvastatin 80-mg loading dose before PCI then followed by 40-mg daily for one
      month and a maintenance dose of 20-mg qd thereafter(n=50); Group 2:received atorvastatin
      40-mg qd after PCI for one month and a maintenance dose of 20-mg qd thereafter(n=50); Group
      3: received atorvastatin 20-mg qd after PCI (n=50).Before PCI,all subjects received oral
      administration of aspirin 300mg and clopidogrel 300mg.Levels of creatine
      kinase,CK-MB(creatine kinase-MB),were measured to estimate myocardial damage
      degree.HS-CRP(high sensitivity C -reactive protein),NO(NO synthase),SAA(Serum amyloid A) were
      measured at preoperation 1 hour,postoperative 24 and 72 hours,7days after PCI. To compare
      echocardiography changes among three groups.Patients enrolled in the study need to receive
      follow-up survey which was carried out by clinical doctors.Hence,MACEs were analyzed during
      6-month follow-up.So, the aim of our study is to evaluate the clinical significance of
      loading dosage of atorvastatin therapy and analyze the mechanism underlying it.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACEs (Major adverse cardiac events)</measure>
    <time_frame>follow-up for 6 months</time_frame>
    <description>MACEs were compared among three groups during follow-up in STEMI patients undergoing emergency PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic changes</measure>
    <time_frame>postoperative 6 month</time_frame>
    <description>to compare echocardiographic changes ( left ventricular ejection fraction(LVEF); Left Ventricular Internal Diameter diastolic(LVIDd);Left Ventricular Internal Diameter systolic (LVIDs),Left Ventricular Enddiastolic Volume(LVEDV);Left Ventricular Endsystolic Volume(LVESV)at postoperative 6 month among three groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HS-CRP,NO,SAA values</measure>
    <time_frame>preoperation 1 hour,postoperative 24 and 72 hours,postoperative 7 days</time_frame>
    <description>to compare hs-crp,no,saa values at differnt treatment period among three groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK,CK-MB</measure>
    <time_frame>preoperation 1hour,postoperation 4/8/12/16/20/24hours</time_frame>
    <description>to estimate myocardial damage degree among three groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST(glutamic-oxalacetic transaminease ),ALT(glutamic-pyruvic transaminase),LDL(low density lipoprotein cholesterin),TG(triglyceride)</measure>
    <time_frame>preoperation 1 hour,postoperation 24 and 72hours,postoperation 7 days</time_frame>
    <description>to monitor adverse drug reaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <condition>(STEMI)</condition>
  <arm_group>
    <arm_group_label>group 1, Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 , Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 , Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 will be administered with atorvastatin 20mg per day until the end of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial</description>
    <arm_group_label>group 1, Atorvastatin</arm_group_label>
    <arm_group_label>group 2 , Atorvastatin</arm_group_label>
    <arm_group_label>group 3 , Atorvastatin</arm_group_label>
    <other_name>lipitol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Clinical diagnosis of STEMI less than 12 hours 2.Eligible for emergency PCI

        Exclusion Criteria:

          -  1.Contradiction to atorvastatin 2.Contradiction to aspirin, clopidogrel and contrast
             medium 3.Life expectancy less than 3 months 4.Tumor or inflammatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HuiLiang Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology of General Hospital of Chinese People's Armed Police Forces</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HuiLiang LIU, Doctor</last_name>
    <phone>86-10-57976531</phone>
    <email>lhl518@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Yang, Doctor</last_name>
    <phone>86-10-57976533</phone>
    <email>yangyongfmmu@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Chinese People's Armed Police Forces</name>
      <address>
        <city>BeiJing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HuiIiang Liu, Doctor</last_name>
      <phone>86-10-57976531</phone>
      <email>lhl518@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yong Yang, Doctor</last_name>
      <phone>86-10-57976533</phone>
      <email>672862837@qq.com;yangyongfmmu@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>HuiLiang Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Yang, Doctors</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenwen Yuan, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med. 2004 Nov;4(4):385-93. Review.</citation>
    <PMID>15861319</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006 Jan 26;106(3):291-7. Review.</citation>
    <PMID>16337036</PMID>
  </results_reference>
  <results_reference>
    <citation>Katayama T, Nakashima H, Yonekura T, Honda Y, Suzuki S, Yano K. [Significance of acute-phase inflammatory reactants as an indicator of prognosis after acute myocardial infarction: which is the most useful predictor?]. J Cardiol. 2003 Aug;42(2):49-56. Japanese.</citation>
    <PMID>12964514</PMID>
  </results_reference>
  <results_reference>
    <citation>Topol EJ. Intensive statin therapy--a sea change in cardiovascular prevention. N Engl J Med. 2004 Apr 8;350(15):1562-4. Epub 2004 Mar 8.</citation>
    <PMID>15007111</PMID>
  </results_reference>
  <results_reference>
    <citation>Albrecht C, Kaeppel N, Gauglitz G. Two immunoassay formats for fully automated CRP detection in human serum. Anal Bioanal Chem. 2008 Jul;391(5):1845-52. doi: 10.1007/s00216-008-2093-x. Epub 2008 May 3.</citation>
    <PMID>18454286</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu TL, I Chen Tsai, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT. Establishment of an in-house ELISA and the reference range for serum amyloid A (SAA): complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta. 2007 Feb;376(1-2):72-6. Epub 2006 Jul 15.</citation>
    <PMID>16916504</PMID>
  </results_reference>
  <results_reference>
    <citation>Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, Tentolouris C, Marinou K, Koumallos N, Stefanadis C. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005 Sep 20;46(6):1101-9.</citation>
    <PMID>16168297</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Cardiology of General Hospital of Chinese People's Armed Police Forces</name_title>
    <organization>Department of Cardiology of General Hospital of Chinese People's Armed Police Forces</organization>
  </responsible_party>
  <keyword>ST-elevation myocardial infarction(STEMI)</keyword>
  <keyword>emergency percutaneous coronary intervention(PCI)</keyword>
  <keyword>lipitor or Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

